Purpose-built models that titrate orexin tone to intermediate levels and assess outcomes beyond cataplexy—such as sleep–wake stability, REM propensity, and autonomic regulation—are therefore essential to extend therapeutic discovery across the full disease spectrum [3,64]. This evidence concerns the gene HCRT and Cataplexy.